Vol. 281, Issue 3, 1312-1316, 1997

Effect of Cisapride and Renzapride on Gastrointestinal Motility and Plasma Motilin Concentration in Dogs

C. W. Song, K. Y. Lee, C. D. Kim, T-M. Chang and W. Y. Chey

Konar Center for Digestive and Liver Diseases, Department of Medicine, University of Rochester Medical Center, Rochester, New York

The effects of cisapride and renzapride (BRL 24924), on plasma concentration of motilin and gastroduodenal motility were studied in seven dogs with implanted force transducers in the antrum and duodenum. In the interdigestive state, the i.v. administration of cisapride (5 mg) or renzapride (5 mg) administered in phase I resulted in a prompt and marked increase in plasma motilin concentration and in gastroduodenal motility. Mean plasma motilin levels during the first 30 min after cisapride and after renzapride injection were 85.0 ± 6.5 (± S.E.) and 96.1 ± 6.3 pM., respectively. These values were significantly greater (P < .001) than those for the corresponding time period of the control cycle, 52.2 ± 5.6 and 57.4 ± 5.3 pM (mean phase III level, 120 ± 8.1 pM), respectively. The increases in the motilin level after cisapride or renzapride coincided with significant increases in contractile activities of the antrum to 43.2 ± 5.3% and 44.9 ± 4.6% and of the duodenum to 28.4 ± 3.1% and 34.2 ± 2.2% of phase III activity (100%) from that in the corresponding control period, 0.7 ± 0.4% and 0.2 ± 0.1%, respectively. The changes in both plasma motilin and motility in response to the two drugs were abolished completely by the i.v. administration of atropine. The drugs also enhanced the meal-induced contractile activities of the antrum as well as the duodenum but failed to influence the postprandial plasma motilin concentration. We conclude that cisapride and renzapride have similar effects on plasma motilin and gastroduodenal motility: 1) the two drugs increase plasma motilin levels and stimulate gastroduodenal motility in the interdigestive state, and 2) in the digestive state, both drugs enhance motility without influencing the plasma motilin levels.